Unveiling TTI-101 as a Novel Approach in Pulmonary Fibrosis & Interstitial Lung Disease Treatment
Time: 4:15 pm
day: Day Two
Details:
• Exploring TTI-101, an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3) and its implications in IPF and ILD
• Examining the comprehensive Phase 2 multicenter study of TTI-101, explore the study’s scope, objectives, patient selection criteria, endpoint selection, and the study methodology